XPHARMA

XPHARMA has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €889,956 and a net result of €318,475. Equity is growing by about 75% per year across the filed financial years. Its solvency ranks better than 46% of 22,595 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).